(Q51378588)

4 April 2018

title

Sitagliptin lowers glucagon and improves glucose tolerance in prediabetic obese SHROB rats. (English)

1 reference

4 April 2018

0 references

1 reference

7

1 reference

4 April 2018

author name string

Brian Chen

1

1 reference

4 April 2018

Alex Moore

2

1 reference

4 April 2018

Liza V S Escobedo

3

1 reference

4 April 2018

Matthew S Koletsky

4

1 reference

4 April 2018

Diana Hou

5

1 reference

4 April 2018

Richard J Koletsky

6

1 reference

4 April 2018

publication date

23 February 2011

1 reference

4 April 2018

Experimental Biology and Medicine

published in

1 reference

4 April 2018

volume

236

1 reference

4 April 2018

issue

3

1 reference

4 April 2018

page(s)

309-314

1 reference

4 April 2018

Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.

cites work

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010161

Sitagliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010161

Peptides that regulate food intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010161

Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010161

Molecular pathology in the obese spontaneous hypertensive Koletsky rat: a model of syndrome X.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010161

Effects of pioglitazone on increases in visceral fat accumulation and oxidative stress in spontaneously hypertensive hyperlipidemic rats fed a high-fat diet and sucrose solution

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010161

Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010161

Impact of NIDDM on mortality and causes of death in Pima Indians

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010161

Therapeutic strategies based on glucagon-like peptide 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010161

Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010161

Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010161

Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010161

Type 2 diabetic patients have increased gluconeogenic efficiency to substrate availability, but intact autoregulation of endogenous glucose production

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010161

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010161

Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010161

21 January 2018

Identifiers

DOI

10.1258/EBM.2010.010161

1 reference

4 April 2018

PubMed ID

21345931

1 reference

4 April 2018